{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T23:50:41Z","timestamp":1793922641813,"version":"4.8.0"},"reference-count":85,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T00:00:00Z","timestamp":1600387200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.biopha.2020.110779","type":"journal-article","created":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T01:27:22Z","timestamp":1600824442000},"page":"110779","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Therapeutic advances in Fabry disease: The future awaits"],"prefix":"10.1016","volume":"131","author":[{"given":"Sam","family":"Kant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed G.","family":"Atta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.biopha.2020.110779_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbagen.2019.129437","article-title":"Progress in the understanding and treatment of Fabry disease","volume":"1864","author":"Miller","year":"2020","journal-title":"Biochim. Biophys. Acta (BBA)"},{"issue":"12","key":"10.1016\/j.biopha.2020.110779_bib0010","doi-asserted-by":"crossref","first-page":"3454","DOI":"10.1002\/jcp.25807","article-title":"Impact of lysosomal storage disorders on biology of mesenchymal stem cells: evidences from in vitro silencing of glucocerebrosidase (GBA) and alpha\u2010galactosidase A (GLA) enzymes","volume":"232","author":"Squillaro","year":"2017","journal-title":"J. Cell. Physiol."},{"issue":"2","key":"10.1016\/j.biopha.2020.110779_bib0015","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.bbadis.2011.11.001","article-title":"Globotriaosylceramide is correlated with oxidative stress and inflammation in Fabry patients treated with enzyme replacement therapy","volume":"1822","author":"Biancini","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"issue":"1","key":"10.1016\/j.biopha.2020.110779_bib0020","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ymgme.2013.02.003","article-title":"Fabry disease peripheral blood immune cells release inflammatory cytokines: role of globotriaosylceramide","volume":"109","author":"De Francesco","year":"2013","journal-title":"Mol. Genet. Metab."},{"issue":"6","key":"10.1016\/j.biopha.2020.110779_bib0025","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/ki.2010.484","article-title":"Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease","volume":"79","author":"Najafian","year":"2011","journal-title":"Kidney Int."},{"key":"10.1016\/j.biopha.2020.110779_bib0030","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3389\/fcvm.2016.00007","article-title":"Electrocardiographic changes and arrhythmia in Fabry disease","volume":"3","author":"Namdar","year":"2016","journal-title":"Front. Cardiovasc. Med."},{"issue":"1","key":"10.1016\/j.biopha.2020.110779_bib0035","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"issue":"3","key":"10.1016\/j.biopha.2020.110779_bib0040","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1053\/j.semperi.2015.03.005","article-title":"Newborn screening for lysosomal storage disorders","volume":"39","author":"Matern","year":"2015","journal-title":"Semin. Perinatol."},{"issue":"1","key":"10.1016\/j.biopha.2020.110779_bib0045","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/cge.12613","article-title":"X-chromosome inactivation in female patients with Fabry disease","volume":"89","author":"Echevarria","year":"2016","journal-title":"Clin. Genet."},{"issue":"2","key":"10.1016\/j.biopha.2020.110779_bib0050","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ymgme.2007.09.013","article-title":"Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry","volume":"93","author":"Wilcox","year":"2008","journal-title":"Mol. Genet. Metab."},{"issue":"5","key":"10.1016\/j.biopha.2020.110779_bib0055","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2016090964","article-title":"Characterization of classical and nonclassical Fabry disease: a multicenter study","volume":"28","author":"Arends","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"issue":"8","key":"10.1016\/j.biopha.2020.110779_bib0060","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2020.110779_bib0065","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s10545-006-0221-3","article-title":"The effect of 12-month enzyme replacement therapy on myocardial perfusion in patients with Fabry disease","volume":"29","author":"Kalliokoski","year":"2006","journal-title":"J. Inherit. Metab. Dis."},{"issue":"6","key":"10.1016\/j.biopha.2020.110779_bib0070","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1093\/ndt\/gfq306","article-title":"Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy","volume":"26","author":"Sanchez-Nino","year":"2010","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.biopha.2020.110779_bib0075","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.neulet.2015.01.084","article-title":"The Fabry disease-associated lipid Lyso-Gb3 enhances voltage-gated calcium currents in sensory neurons and causes pain","volume":"594","author":"Choi","year":"2015","journal-title":"Neurosci. Lett."},{"issue":"20","key":"10.1016\/j.biopha.2020.110779_bib0080","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1093\/hmg\/ddv291","article-title":"Lyso-Gb3 activates Notch1 in human podocytes","volume":"24","author":"Sanchez-Ni\u00f1o","year":"2015","journal-title":"Hum. Mol. Genet."},{"issue":"2","key":"10.1016\/j.biopha.2020.110779_bib0085","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ymgme.2017.07.002","article-title":"Genotype, phenotype and disease severity reflected by serum LysoGb3 levels in patients with Fabry disease","volume":"123","author":"Nowak","year":"2018","journal-title":"Mol. Genet. Metab."},{"issue":"8","key":"10.1016\/j.biopha.2020.110779_bib0090","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proceed. Natl. Acad. Sci."},{"issue":"5","key":"10.1016\/j.biopha.2020.110779_bib0095","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2016090964","article-title":"Characterization of classical and nonclassical fabry disease: a multicenter study","volume":"28","author":"Arends","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"issue":"4","key":"10.1016\/j.biopha.2020.110779_bib0100","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1365-2133.1898.tb16317.x","article-title":"A case of \u201cAngeio-Keratoma.\u201d*","volume":"10","author":"ANDERSON","year":"1898","journal-title":"Br. J. Dermatol."},{"issue":"21","key":"10.1016\/j.biopha.2020.110779_bib0105","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJM196705252762101","article-title":"Enzymatic defect in Fabry\u2019s disease","volume":"276","author":"Brady","year":"1967","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.biopha.2020.110779_bib0110","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human \u03b1-Galactosidase a replacement therapy in Fabry\u2019s disease","volume":"345","author":"Eng","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.biopha.2020.110779_bib0115","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.biopha.2020.110779_bib0120","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ymgme.2008.03.003","article-title":"Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3","volume":"94","author":"Vedder","year":"2008","journal-title":"Mol. Genet. Metab."},{"issue":"9","key":"10.1016\/j.biopha.2020.110779_bib0125","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1681\/ASN.2006121400","article-title":"Antiproteinuric therapy and Fabry nephropathy: sustained reduction of Proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta","volume":"18","author":"Tahir","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"issue":"5","key":"10.1016\/j.biopha.2020.110779_bib0130","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1681\/ASN.2006080816","article-title":"Sustained, long-term renal stabilization after 54 months of agalsidase \u03b2 therapy in patients with Fabry disease","volume":"18","author":"Germain","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"issue":"2","key":"10.1016\/j.biopha.2020.110779_bib0135","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","article-title":"Agalsidase-beta therapy for advanced Fabry disease: a randomized trial","volume":"146","author":"Banikazemi","year":"2007","journal-title":"Ann. Intern. Med."},{"issue":"5","key":"10.1016\/j.biopha.2020.110779_bib0140","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1681\/ASN.2006111263","article-title":"Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing","volume":"18","author":"Schiffmann","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"issue":"2","key":"10.1016\/j.biopha.2020.110779_bib0145","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/ndt\/gfi152","article-title":"Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting","volume":"21","author":"Schiffmann","year":"2006","journal-title":"Nephrol. Dial. Transplant."},{"issue":"11","key":"10.1016\/j.biopha.2020.110779_bib0150","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1161\/01.CIR.0000091253.71282.04","article-title":"Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study","volume":"108","author":"Weidemann","year":"2003","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.biopha.2020.110779_bib0155","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/hrt.2006.104026","article-title":"Effects of enzyme replacement therapy on the cardiomyopathy of Anderson\u2013Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa","volume":"94","author":"Hughes","year":"2008","journal-title":"Heart"},{"issue":"2","key":"10.1016\/j.biopha.2020.110779_bib0160","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1399-0004.2004.00284.x","article-title":"Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry\u2019s disease","volume":"66","author":"Spinelli","year":"2004","journal-title":"Clin. Genet."},{"issue":"10","key":"10.1016\/j.biopha.2020.110779_bib0165","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.amjcard.2005.11.087","article-title":"Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry\u2019s cardiomyopathy","volume":"97","author":"Beer","year":"2006","journal-title":"Am. J. Cardiol."},{"issue":"1","key":"10.1016\/j.biopha.2020.110779_bib0170","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s10545-006-0221-3","article-title":"The effect of 12-month enzyme replacement therapy on myocardial perfusion in patients with Fabry disease","volume":"29","author":"Kalliokoski","year":"2006","journal-title":"J. Inherit. Metab. Dis."},{"issue":"6","key":"10.1016\/j.biopha.2020.110779_bib0175","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s00228-007-0460-8","article-title":"Fabry disease and treatment with agalsidase alpha: unsuspected cardiac arrhythmia in two heterozygous women","volume":"64","author":"Mougenot","year":"2008","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.biopha.2020.110779_bib0180","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/B978-0-444-62702-5.00017-2","article-title":"Chapter 17 - Fabry disease","volume":"132","author":"Schiffmann","year":"2015","journal-title":"Handb. Clin. Neurol."},{"issue":"4","key":"10.1016\/j.biopha.2020.110779_bib0185","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1161\/CIRCULATIONAHA.108.794529","article-title":"Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: evidence for a better outcome with early treatment","volume":"119","author":"Weidemann","year":"2009","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.biopha.2020.110779_bib0190","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/jmedgenet-2014-102797","article-title":"Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease","volume":"52","author":"Germain","year":"2015","journal-title":"J. Med. Genet."},{"issue":"1","key":"10.1016\/j.biopha.2020.110779_bib0195","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1681\/ASN.2012030316","article-title":"Agalsidase benefits renal histology in young patients with Fabry disease","volume":"24","author":"T\u00f8ndel","year":"2013","journal-title":"J. Am. Soc. Nephrol."},{"issue":"2","key":"10.1016\/j.biopha.2020.110779_bib0200","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ymgme.2017.05.001","article-title":"Favourable effect of early versus late start of enzyme replacement therapy on plasma globotriaosylsphingosine levels in men with classical Fabry disease","volume":"121","author":"Arends","year":"2017","journal-title":"Mol. Genet. Metab."},{"issue":"8","key":"10.1016\/j.biopha.2020.110779_bib0205","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0182379","article-title":"Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry disease: analysis of prognostic factors","volume":"12","author":"Arends","year":"2017","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.biopha.2020.110779_bib0210","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/jmedgenet-2017-104863","article-title":"Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study","volume":"55","author":"Arends","year":"2018","journal-title":"J. Med. Genet."},{"issue":"3","key":"10.1016\/j.biopha.2020.110779_bib0215","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ymgme.2018.04.007","article-title":"The effect of enzyme replacement therapy on clinical outcomes in paediatric patients with Fabry disease \u2013 a systematic literature review by a European panel of experts","volume":"126","author":"Spada","year":"2019","journal-title":"Mol. Genet. Metab."},{"issue":"5","key":"10.1016\/j.biopha.2020.110779_bib0220","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/ndt\/gfw094","article-title":"Reaccumulation of globotriaosylceramide in podocytes after agalsidase dose reduction in young Fabry patients","volume":"32","author":"Skrunes","year":"2017","journal-title":"Nephrol. Dial. Transplant."},{"issue":"6","key":"10.1016\/j.biopha.2020.110779_bib0225","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s10545-014-9724-5","article-title":"Effective clearance of GL-3 in a human iPSC-derived cardiomyocyte model of Fabry disease","volume":"37","author":"Itier","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"issue":"19","key":"10.1016\/j.biopha.2020.110779_bib0230","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1161\/CIRCULATIONAHA.108.841494","article-title":"Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy","volume":"119","author":"Thurberg","year":"2009","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.biopha.2020.110779_bib0235","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1046\/j.1523-1755.2002.00675.x","article-title":"Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy","volume":"62","author":"Thurberg","year":"2002","journal-title":"Kidney Int."},{"key":"10.1016\/j.biopha.2020.110779_bib0240","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/bs.apcsb.2015.10.001","article-title":"Chapter eight - personalized pharmacoperones for lysosomal storage disorder: approach for next-generation treatment","volume":"102","author":"Syed Haneef","year":"2016","journal-title":"Adv. Protein Chem. Struct. Biol."},{"issue":"7","key":"10.1016\/j.biopha.2020.110779_bib0245","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1038\/mt.2015.62","article-title":"Pharmacological chaperone therapy: preclinical development, clinical translation, and prospects for the treatment of lysosomal storage disorders","volume":"23","author":"Parenti","year":"2015","journal-title":"Mol. Ther."},{"issue":"13","key":"10.1016\/j.biopha.2020.110779_bib0250","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1046\/j.1432-1327.2000.01457.x","article-title":"In vitro inhibition and intracellular enhancement of lysosomal \u03b1\u2010galactosidase A activity in Fabry lymphoblasts by 1\u2010deoxygalactonojirimycin and its derivatives","volume":"267","author":"Asano","year":"2000","journal-title":"Eur. J. Biochem."},{"issue":"1","key":"10.1016\/j.biopha.2020.110779_bib0255","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1096\/fj.04-2375com","article-title":"A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding disorder","volume":"19","author":"Yam","year":"2005","journal-title":"Faseb J."},{"issue":"1","key":"10.1016\/j.biopha.2020.110779_bib0260","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/4801","article-title":"Accelerated transport and maturation of lysosomal \u03b1\u2013galactosidase A in Fabry lymphoblasts by an enzyme inhibitor","volume":"5","author":"Fan","year":"1999","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.biopha.2020.110779_bib0265","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","article-title":"Treatment of Fabry\u2019s disease with the pharmacologic chaperone migalastat","volume":"375","author":"Germain","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.biopha.2020.110779_bib0270","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/jmedgenet-2016-104178","article-title":"Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study","volume":"54","author":"Hughes","year":"2017","journal-title":"J. Med. Genet."},{"issue":"5","key":"10.1016\/j.biopha.2020.110779_bib0275","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/cpt.1321","article-title":"Oral chaperone therapy migalastat for treating fabry disease: enzymatic response and serum biomarker changes after 1 year","volume":"105","author":"M\u00fcntze","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.biopha.2020.110779_bib0280","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ekir.2019.11.013","article-title":"Current and investigational therapeutics for Fabry disease","volume":"5","author":"Felis","year":"2020","journal-title":"Kidney Int. Rep."},{"key":"10.1016\/j.biopha.2020.110779_bib0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2020.08.012","article-title":"In vitro and in vivo amenability to migalastat in Fabry disease","author":"Lenders","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.biopha.2020.110779_bib0290","unstructured":"Galafold Amenability Table [https:\/\/www.galafoldamenabilitytable.com\/hcp]. Date accessed: 10th September 2020."},{"key":"10.1016\/j.biopha.2020.110779_bib0295","doi-asserted-by":"crossref","first-page":"912","DOI":"10.12688\/f1000research.8010.1","article-title":"The potential of plants as a system for the development and production of human biologics","volume":"5","author":"Chen","year":"2016","journal-title":"F1000 Res."},{"issue":"3","key":"10.1016\/j.biopha.2020.110779_bib0300","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/jimd.12080","article-title":"Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: a 1\u2010year Phase 1\/2 clinical trial","volume":"42","author":"Schiffmann","year":"2019","journal-title":"J. Inherit. Metab. Dis."},{"issue":"2","key":"10.1016\/j.biopha.2020.110779_bib0305","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ymgme.2014.08.002","article-title":"Characterization of a chemically modified plant cell culture expressed human \u03b1-galactosidase-A enzyme for treatment of Fabry disease","volume":"114","author":"Kizhner","year":"2015","journal-title":"Mol. Genet. Metab."},{"issue":"10","key":"10.1016\/j.biopha.2020.110779_bib0310","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/nbt.2682","article-title":"Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction","volume":"31","author":"Zangi","year":"2013","journal-title":"Nat. Biotechnol."},{"issue":"3","key":"10.1016\/j.biopha.2020.110779_bib0315","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1172\/JCI65351","article-title":"Modified Foxp3 mRNA protects against asthma through an IL-10\u2013dependent mechanism","volume":"123","author":"Mays","year":"2013","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.biopha.2020.110779_bib0320","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1038\/mt.2012.7","article-title":"Increased erythropoiesis in mice injected with submicrogram quantities of pseudouridine-containing mRNA encoding erythropoietin","volume":"20","author":"Karik\u00f3","year":"2012","journal-title":"Mol. Ther."},{"issue":"2","key":"10.1016\/j.biopha.2020.110779_bib0325","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/nbt.1733","article-title":"Expression of therapeutic proteins after delivery of chemically modified mRNA in mice","volume":"29","author":"Kormann","year":"2011","journal-title":"Nat. Biotechnol."},{"issue":"4","key":"10.1016\/j.biopha.2020.110779_bib0330","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.ymthe.2019.03.001","article-title":"Improved efficacy in a Fabry disease model using a systemic mRNA liver depot system as compared to enzyme replacement therapy","volume":"27","author":"DeRosa","year":"2019","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2020.110779_bib0335","doi-asserted-by":"crossref","first-page":"14630","DOI":"10.1038\/ncomms14630","article-title":"Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge","volume":"8","author":"Pardi","year":"2017","journal-title":"Nat. Commun."},{"issue":"10101","key":"10.1016\/j.biopha.2020.110779_bib0340","first-page":"1511","article-title":"Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial","volume":"390","author":"Alberer","year":"2017","journal-title":"The Lancet (British edition)"},{"issue":"10","key":"10.1016\/j.biopha.2020.110779_bib0345","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/gt.2016.46","article-title":"Therapeutic efficacy in a hemophilia B model using a biosynthetic mRNA liver depot system","volume":"23","author":"DeRosa","year":"2016","journal-title":"Gene Ther."},{"issue":"4","key":"10.1016\/j.biopha.2020.110779_bib0350","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.ajhg.2019.02.003","article-title":"Systemic mRNA therapy for the treatment of Fabry disease: preclinical studies in wild-type mice, Fabry mouse model, and wild-type non-human Primates","volume":"104","author":"Zhu","year":"2019","journal-title":"Am. J. Hum. Genet."},{"issue":"1","key":"10.1016\/j.biopha.2020.110779_bib0355","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/00007890-198807000-00011","article-title":"Long-term follow-up of the first successful bone marrow transplantation in Gaucher Disease","volume":"46","author":"Ringd\u00e9n","year":"1988","journal-title":"Transplantation"},{"issue":"8249","key":"10.1016\/j.biopha.2020.110779_bib0360","first-page":"709","article-title":"Reversal of clinical features of Hurler\u2019s disease and biochemical improvement after treatment by bone-marrow transplantation","volume":"318","author":"HOBBS","year":"1981","journal-title":"The Lancet (British edition)"},{"issue":"5","key":"10.1016\/j.biopha.2020.110779_bib0365","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1056\/NEJMra1706910","article-title":"Gene therapy","volume":"381","author":"High","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.biopha.2020.110779_bib0370","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1016\/j.ymgme.2018.12.187","article-title":"Liver-targeted AAV gene therapy vectors produced by a clinical scale manufacturing process result in high, continuous therapeutic levels of enzyme activity and effective substrate reduction in mouse model of Fabry disease","volume":"126","author":"Huston","year":"2019","journal-title":"Mol. Genet. Metab."},{"issue":"Supplement 1","key":"10.1016\/j.biopha.2020.110779_bib0375","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1182\/blood-2018-99-116632","article-title":"Efficacy evaluation of liver-directed gene therapy in Fabry mice","volume":"132","author":"Kia","year":"2018","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.biopha.2020.110779_bib0380","first-page":"S83","article-title":"AAV gene therapy for the treatment of Fabry disease: a novel capsid with improved tropism to heart, kidney and CNS and improved GLA expression","volume":"126","author":"Kevany","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.biopha.2020.110779_bib0385","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.omtm.2017.05.003","article-title":"Lentivector iterations and pre-clinical Scale-Up\/Toxicity testing: targeting mobilized CD34+ cells for correction of Fabry disease","volume":"5","author":"Huang","year":"2017","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"2","key":"10.1016\/j.biopha.2020.110779_bib0390","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1016\/j.ymgme.2018.12.248","article-title":"FACTs Fabry gene therapy clinical trial: two-year data","volume":"126","author":"Medin","year":"2019","journal-title":"Mol. Genet. Metab."},{"issue":"2","key":"10.1016\/j.biopha.2020.110779_bib0395","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nrd.2017.214","article-title":"Emptying the stores: lysosomal diseases and therapeutic strategies. Nature reviews","volume":"17","author":"Platt","year":"2017","journal-title":"Drug discovery"},{"issue":"Issue 1","key":"10.1016\/j.biopha.2020.110779_bib0400","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2147\/TCRM.S73226","article-title":"Profile of eliglustat tartrate in the management of Gaucher disease","volume":"12","author":"Sechi","year":"2016","journal-title":"Ther. Clin. Risk Manage."},{"issue":"1","key":"10.1016\/j.biopha.2020.110779_bib0405","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1358\/dot.2006.42.1.937457","article-title":"Miglustat: substrate reduction therapy for glycosphingolipid lysosomal storage disorders","volume":"42","author":"Lachmann","year":"2006","journal-title":"Drugs Today"},{"issue":"1\u20132","key":"10.1016\/j.biopha.2020.110779_bib0410","doi-asserted-by":"crossref","first-page":"S139","DOI":"10.1016\/j.ymgme.2016.11.369","article-title":"Lucerastat, an iminosugar for substrate reduction therapy in Fabry disease: preclinical evidence","volume":"120","author":"Welford","year":"2017","journal-title":"Mol. Genet. Metab."},{"issue":"1","key":"10.1016\/j.biopha.2020.110779_bib0415","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13023-017-0565-9","article-title":"Lucerastat, an iminosugar with potential as substrate reduction therapy for glycolipid storage disorders: safety, tolerability, and pharmacokinetics in healthy subjects","volume":"12","author":"Gu\u00e9rard","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"issue":"4","key":"10.1016\/j.biopha.2020.110779_bib0420","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/cpt.790","article-title":"Lucerastat, an iminosugar for substrate reduction therapy: tolerability, pharmacodynamics, and pharmacokinetics in patients with fabry disease on enzyme replacement","volume":"103","author":"Gu\u00e9rard","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"issue":"Supplement_3","key":"10.1016\/j.biopha.2020.110779_bib0425","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfaa142.P0062","article-title":"P0062glucosylceramide synthase inhibition with Venglustat in classic Fabry Disease patients leads to progressive reduction of endothelial cell globotriaosylceramide inclusion volume","volume":"35","author":"Mauer","year":"2020","journal-title":"Nephrol. Dial. Transplant."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332220309720?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332220309720?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T18:53:54Z","timestamp":1766084034000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332220309720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":85,"alternative-id":["S0753332220309720"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2020.110779","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic advances in Fabry disease: The future awaits","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2020.110779","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"110779"}}